A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease.

e trial, although both the secondary outcomes of CV and all-cause mortality appeared to be significantly reduced.[ 25 ] The EXSCEL trial enrolled 14,752 subjects, with most having overt CVD, and showed a directionally lower risk of outcomes for exenatide compared with a placebo, but this difference did not reach statistical significance.[ 26 ] Lixisenatide, which was tested in 6,068 patients with acute coronary syndrome in the ELIXA trial, showed no signal for any reduction in MACE.[ 27 ] The HARMONY Outcomes randomised 9,463 participants with CVD, finding albiglutide to be superior to a placebo with respect to MACE.[ 28 ] Despite these findings, the drug’s manufacturer has withdrawn it from the worldwide market due to disappointing sales.

also in 111,027 other papers